RESUMO
Testicular cancer (TCa) is a rare malignancy affecting young men worldwide. Sociodemographic factors, especially socioeconomic level (SEL) and healthcare access, seem to impact TCa incidence and outcomes, particularly among Hispanic populations. However, limited research has explored these variables in Hispanic groups. This study aimed to investigate sociodemographic and clinical factors in Mexico and their role in health disparities among Hispanic TCa patients. We retrospectively analyzed 244 Mexican TCa cases between 2007 and 2020 of a representative cohort with diverse social backgrounds from a national reference cancer center. Logistic regression identified risk factors for fatality: non-seminoma histology, advanced stage, and lower education levels. Age showed a significant trend as a risk factor. Patient delay and healthcare distance lacked significant associations. Inadequate treatment response and chemotherapy resistance were more likely in advanced stages, while higher education positively impacted treatment response. Cox regression highlighted non-seminoma histology, below-median SEL, higher education, and advanced-stage survival rates. Survival disparities emerged based on tumor histology and patient SEL. This research underscores the importance of comprehensive approaches that integrate sociodemographic, biological, and environmental factors to address health disparities improving outcomes through personalized interventions in Hispanic individuals with TCa.
RESUMO
Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in non-seminomatous germ-cell tumor (NSTGCTs) is a complex procedure. We evaluated whether 3D computed tomography (CT) rendering and their radiomic analysis help predict resectability by junior surgeons. The ambispective analysis was performed between 2016-2021. A prospective group (A) of 30 patients undergoing CT was segmented using the 3D Slicer software while a retrospective group (B) of 30 patients was evaluated with conventional CT (without 3D reconstruction). CatFisher's exact test showed a p-value of 0.13 for group A and 1.0 for Group B. The difference between the proportion test showed a p-value of 0.009149 (IC 0.1-0.63). The proportion of the correct classification showed a p-value of 0.645 (IC 0.55-0.87) for A, and 0.275 (IC 0.11-0.43) for Group B. Furthermore, 13 shape features were extracted: elongation, flatness, volume, sphericity, and surface area, among others. Performing a logistic regression with the entire dataset, n = 60, the results were: Accuracy: 0.7 and Precision: 0.65. Using n = 30 randomly chosen, the best result obtained was Accuracy: 0.73 and Precision: 0.83, with a p-value: 0.025 for Fisher's exact test. In conclusion, the results showed a significant difference in the prediction of resectability with conventional CT versus 3D reconstruction by junior surgeons versus experienced surgeons. Radiomic features used to elaborate an artificial intelligence model improve the prediction of resectability. The proposed model could be of great support in a university hospital, allowing it to plan the surgery and to anticipate complications.
RESUMO
BACKGROUND: Recent studies have shown that the classification of high-grade urothelial carcinoma non-muscle invasive (HGBCNMI) based on molecular subtypes might be a valuable strategy to identify patients with a worse clinical prognosis. OBJECTIVE: Determine the effect of the luminal and basal molecular subtype determined by immunistochemical on prognosis in patients with HGBC in Mexican population. METHODS: Phenotypes were evaluated by immunohistochemical staining of luminal (GATA3, FOXA1) and basal (CK5/6, CK14) markers in paraffin-embedded tissue samples from 45 patients with a diagnosis of HGBCNMI treated at Instituto Nacional de Cancerología-México (INCan) between 2009 and 2019. The association with prognosis was evaluated using Kaplan-Meier curves and multivariable-adjusted Cox models. RESULTS: HGBCNMI patients showed mean age of 58.77 years (SD: ±12.08 years). We identified expression of the luminal molecular subtype in 35 cases (77.78 %), and 10 cases (22.22 %) with "combined" expression of the molecular subtype (basal and luminal expression). The combined phenotype was statistically more frequent in metastatic cases (p-value = 0.028). In Kaplan-Meier curves, combined expression of luminal and basal molecular markers was associated with disease progression (p-value = 0.002, log-rank test). Cox regression models confirmed this association, which was not influenced by age (p-value = 0.007) or gender (p-value = 0.007). No association of phenotypes with overall survival (p-value = 0.860) or relapse (p-value = 0.5) was observed. CONCLUSION: The combined expression of immunohistochemical markers of the luminal and basal subtype might be considered as predictor for disease progression in patients with HGBCNMI in Mexican population.
Assuntos
Carcinoma de Células de Transição , Neoplasias da Bexiga Urinária , Humanos , Neoplasias da Bexiga Urinária/patologia , Carcinoma de Células de Transição/patologia , Biomarcadores Tumorais/metabolismo , Recidiva Local de Neoplasia , Prognóstico , Progressão da DoençaRESUMO
Bladder cancer (BC) is the most common neoplasm of the urinary tract, which originates in the epithelium that covers the inner surface of the bladder. The molecular BC profile has led to the development of different classifications of non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). However, the genomic BC landscape profile of the Mexican population, including NMIBC and MIBC, is unknown. In this study, we aimed to identify somatic single nucleotide variants (SNVs) and copy number variations (CNVs) in Mexican patients with BC and their associations with clinical and pathological characteristics. We retrospectively evaluated 37 patients treated between 2012 and 2021 at the National Cancer Institute-Mexico (INCan). DNA samples were obtained from paraffin-embedded tumor tissues and exome sequenced. Strelka2 and Lancet packages were used to identify SNVs and insertions or deletions. FACETS was used to determine CNVs. We found a high frequency of mutations in TP53 and KMT2D, gains in 11q15.5 and 19p13.11-q12, and losses in 7q11.23. STAG2 mutations and 1q11.23 deletions were also associated with NMIBC and low histologic grade.
Assuntos
Variações do Número de Cópias de DNA , Proteínas de Ligação a DNA , Proteínas de Neoplasias , Neoplasias da Bexiga Urinária , Humanos , México , Mutação , Invasividade Neoplásica , Estudos Retrospectivos , Neoplasias da Bexiga Urinária/patologia , Proteínas de Ligação a DNA/genética , Proteínas de Neoplasias/genéticaRESUMO
Despite having a favorable response to platinum-based chemotherapies, ~15% of Testicular Germ-Cell Tumor (TGCT) patients are platinum-resistant. Mortality rates among Latin American countries have remained constant over time, which makes the study of this population of particular interest. To gain insight into this phenomenon, we conducted whole-exome sequencing, microarray-based comparative genomic hybridization, and copy number analysis of 32 tumors from a Mexican cohort, of which 18 were platinum-sensitive and 14 were platinum-resistant. We incorporated analyses of mutational burden, driver mutations, and SNV and CNV signatures. DNA breakpoints in genes were also investigated and might represent an interesting research opportunity. We observed that sensitivity to chemotherapy does not seem to be explained by any of the mutations detected. Instead, we uncovered CNVs, particularly amplifications on segment 2q11.1 as a novel variant with chemosensitivity biomarker potential. Our data shed light into understanding platinum resistance in a Latin-origin population.
RESUMO
OBJECTIVE: To report experience in a hospital in Mexico regarding oncological results in overall survival (OS) and specific cancer survival (SCS), the presence of recurrence in the management of residual masses after chemotherapy with lymphadenectomy retroperitoneal for 15 years. METHOD: Between 2004 and 2019, a retrospective study was carried out in a single centre with patients with a germ cell tumor diagnosis who have received first or second line of chemotherapy and who present retroperitoneal residual mass were included have performed RPLND. Sociodemographic characteristics were analyzed, overall and histological survival. RESULTS: 346 patients had inclusion criteria, mean age was 27.6 years, the most affected testis was the left, the most frequent testicular histology was mixed germline. The most frequent retroperitoneal location was paraortic, the most frequent type of RPLND was standard, the most frequent histology was necrosis. Recurrence occurred in 24.2%, mean of 17.1 months, when analyzing individual factors, the most significant was the type of RPLND. The clinical stage, histology of the retroperitoneal tumor and type of RPLND influence mortality. Global follow up of 141 months, OS was 85.5% and SCS was 86.1%, mean of 139.9 months and 141 months respectively. CONCLUSIONS: RPLND is effective in survival and recurrence in advanced disease in patients who present postchemotherapy retroperitoneal tumor and although there is a clear benefit in the resection of retroperitoneal tumors in teratoma, there are conditioning factors that must be analyzed individually.
OBJETIVO: Reportar nuestra experiencia en supervivencia y recurrencia en el manejo de masas residuales posquimioterapia con linfadenectomía retroperitoneal durante 15 años. MÉTODO: Estudio retrospectivo de 2004 a 2019. Se incluyeron pacientes con diagnóstico de tumor de células germinales que habían recibido quimioterapia y presentaron una masa residual retroperitoneal en un solo centro y se les realizó linfadenectomía retroperitoneal. Se analizaron las características sociodemográficas, de supervivencia global e histológicas. RESULTADOS: Cumplían los criterios de inclusión 346 pacientes, con una media de edad de 27.6 años. El testículo más afectado fue el izquierdo, y la histología testicular más frecuente fue germinal mixto. La localización retroperitoneal más frecuente fue paraaórtica, el tipo de linfadenectomía más frecuente fue la estándar y la histología más frecuente fue la necrosis. Se presentó recurrencia en el 24.2% de los pacientes, en una media de 17.1 meses; al analizar los factores individuales, el más significativo fue el tipo de linfadenectomía. El estadio clínico, la histología del tumor retroperitoneal y el tipo de linfadenectomía influyen en la mortalidad. El seguimiento global fue de 141 meses, la supervivencia global fue del 85.5% y la supervivencia específica del cáncer fue del 86.1%, con media de 139.9 y 141 meses, respectivamente. CONCLUSIONES: La linfadenectomía retroperitoneal es efectiva en cuanto a supervivencia y recurrencia en la enfermedad avanzada en pacientes que presentan tumor retroperitoneal posquimioterapia, y aunque existe un claro beneficio en la resección de los tumores retroperitoneales en teratoma, existen factores condicionantes que deben ser analizados de manera individual.
Assuntos
Neoplasias Embrionárias de Células Germinativas , Neoplasias Testiculares , Adulto , Dissecação , Humanos , Excisão de Linfonodo , Masculino , Neoplasias Embrionárias de Células Germinativas/tratamento farmacológico , Neoplasias Embrionárias de Células Germinativas/cirurgia , Espaço Retroperitoneal , Estudos Retrospectivos , Neoplasias Testiculares/tratamento farmacológico , Neoplasias Testiculares/cirurgia , Resultado do TratamentoRESUMO
BACKGROUND: Prostate cancer is the most frequent neoplasm in Mexican men, the research literature contains few studies that address prostate cancer patients and quality of life in Mexico. OBJECTIVE: To validate the Functional Assessment Cancer therapy (FACT-P) scale. METHOD: 201 males 49 to 90 years of age, at any clinical stage of prostate cancer, under treatment or follow-up participated. It's a non-experimental cross-sectional study. Patients were evaluated through the FACT-P jointly with the European Organization for Research and Treatment of Cancer Quality of Life and Hospital Anxiety and Depression Scale. Exploratory analysis examined the factorial structure, and confirmatory analysis to evaluate the adjustment of the exploratory model to the data. RESULTS: A four-factor model that explained 64.65% of the variance, Cronbach's alpha 0.79, and correlations were statistically significant, Pearson's r of 0.146-0.716, p < 0.01 and p < 0.05. Analyses also distinguished metastatic patients from non-metastatic ones. The main indices of the confirmatory model were satisfactory for the adjustment of data and showed an estimate error close to zero. CONCLUSIONS: This Mexican version of FACT-P showed reliability and validity comparable to the original one.
ANTECEDENTES: El cáncer de próstata es la neoplasia más frecuente en los varones mexicanos, pero pocos estudios han abordado la calidad de vida en los pacientes con cáncer de próstata en México. OBJETIVO: Validar la Escala de Evaluación Funcional para el Tratamiento del Cáncer, versión próstata (FACT-P). MÉTODO: 201 pacientes de 49 a 90 años en cualquier etapa clínica, en tratamiento o seguimiento. Diseño de estudio: transversal no experimental. Se usaron el FACT-P, el Inventario de la Organización Europea para la Investigación y Tratamiento del cáncer y Calidad de Vida, y la Escala de Ansiedad y Depresión Hospitalaria. Se realizaron análisis factorial exploratorio y análisis factorial confirmatorio para evaluar el ajuste del modelo de los datos, mediante el método de máxima verosimilitud. RESULTADOS: Se obtuvo un modelo de dos factores y dos indicadores que explicaron el 64.65% de la varianza, alfa de Cronbach 0.79, correlaciones estadísticamente significativas, r de Pearson de 0.146-0.716, p < 0.01 y p < 0.05. La escala discrimina los pacientes sin y con metástasis. Los principales índices del modelo confirmatorio sugieren un modelo estable y parsimonioso, con error próximo a cero, que se ajusta aceptablemente a los datos analizados. CONCLUSIONES: La versión mexicana del FACT-P posee una confiabilidad y una validez adecuadas, similares a las de la original.
Assuntos
Modalidades de Fisioterapia , Qualidade de Vida , Estudos Transversais , Humanos , Masculino , Reprodutibilidade dos Testes , SíndromeRESUMO
Prostate cancer (PCa) is the second most prevalent cancer in men worldwide. Despite the advances understanding the molecular processes driving the onset and progression of this disease, as well as the continued implementation of screening programs, PCa still remains a significant cause of morbidity and mortality, in particular in low-income countries. It is only recently that defects of the translation process, i.e., the synthesis of proteins by the ribosome using a messenger (m)RNA as a template, have begun to gain attention as an important cause of cancer development in different human tissues, including prostate. In particular, the initiation step of translation has been established to play a key role in tumorigenesis. In this review, we discuss the state-of-the-art of three key aspects of protein synthesis in PCa, namely, misexpression of translation initiation factors, dysregulation of the major signaling cascades regulating translation, and the therapeutic strategies based on pharmacological compounds targeting translation as a novel alternative to those based on hormones controlling the androgen receptor pathway.
RESUMO
Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) has found widespread use for the diagnosis of biochemical recurrence of prostate cancer (PCa). Unfortunately, PET/CT is not as widely available; thus a PSMA-targeting compound for scintigraphy is of special interest. The aim of this study was to compare 99mTc-EDDA/HYNIC-iPSMA and 68Ga-PSMA-11 PET/CT qualitatively and semi-quantitatively. Twenty-three patients with metastatic PCa were underwent 99mTc-EDDA/HYNIC-iPSMA SPECT/CT followed by 68Ga-PSMA-11 PET/CT. Gleason score in all patients was obtained. Maximal standardized uptake value (SUVmax) and counts per organ, including the primary and metastatic tumor, were normalized and compared using Pearson's correlation test. Sites considered as positive have increased SUVmax and tumor-to-background ratio (TBR) in comparison with non-diseased organs/tissues (SUVmax =25.2±4.7, 18.4±1.6, 11.4±1.2 (P=0.037) from prostate, bone and lymph nodes versus TBR =35.9±45.2, 15.4±18.9, 19.1±51.7 (P=0.035) for prostate, bone and lymph nodes. 99mTc-HYNIC-iPSMA and 68Ga-PSMA-11 uptake values in the evaluation of the affected nodes were very similar, although their ranges ranged from 5-21 mm (12±7.6). Correlation coefficient was normalized between SUVmax and TBR, demonstrating r values for prostate of r2=0.731; for bone of r2=0.720; and lymph nodes of r2=0.864 (P<0.05 in all cases). Values and confidence interval at the 95% are supporting the equivalency of both parameters in primary tumor and metastases (prostate 95% CI=4.61, 4.38; bone tissue 95% CI=-2.21, 3.41 and lymph node 95% CI=4.67). We conclude that 68Ga-PSMA-11 PET/CT and 99mTc-EDDA/HYNIC-iPSMA SPECT/CT were comparable, supporting the use of 99mTc-EDDA/HYNIC-iPSMA in patients with progressive metastatic castration-resistant PCa.
RESUMO
OBJECTIVES: To evaluate factors affecting the risk of prostate cancer (CaP) and high-grade disease (HGCaP, Gleason score ≥ 7) in a Mexican referral population, with comparison to the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (PCPTRC). METHODS AND MATERIALS: From a retrospective study of 826 patients who underwent prostate biopsy between January 2005 and December 2009 at the Instituto Nacional de Cancerología, Mexico, logistic regression was used to assess the effects of age, prostate-specific antigen (PSA), digital rectal exam (DRE), first-degree family history of CaP, and history of a prior prostate biopsy on CaP and HGCaP, separately. Internal discrimination, goodness-of-fit, and clinical utility of the resulting models were assessed with comparison to the PCPTRC. RESULTS: Rates of both CaP (73.2%) and HGCaP (33.3%) were high among referral patients in this Mexican urology clinic. The PCPTRC generally underestimated the risk of CaP but overestimated the risk of HGCaP. Four factors influencing CaP on biopsy were logPSA, DRE, family history and a prior biopsy history (all P < 0.001). The internal AUC of the logistic model was 0.823 compared with 0.785 of the PCPTRC for CaP (P < 0.001). The same 4 factors were significantly associated with HGCaP as well and the AUC was 0.779 compared with 0.766 of the PCPTRC for HGCaP (P = 0.13). CONCLUSIONS: Lack of screening programs or regular urologic checkups in Mexico imply that men typically first reach specialized clinics with a high cancer risk. This renders diagnostic tools developed on comparatively healthy populations, such as the PCPTRC, of lesser utility. Continued efforts are needed to develop and externally validate new clinical diagnostic tools specific to high-risk referral populations incorporating new biomarkers and more clinical characteristics.
Assuntos
Instituições de Assistência Ambulatorial/estatística & dados numéricos , Próstata/patologia , Neoplasias da Próstata/patologia , Urologia , Idoso , Biópsia , Exame Retal Digital , Saúde da Família , Humanos , Modelos Logísticos , Masculino , México , Pessoa de Meia-Idade , Gradação de Tumores , Prognóstico , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/prevenção & controle , Encaminhamento e Consulta/estatística & dados numéricos , Estudos Retrospectivos , Medição de Risco , Fatores de RiscoRESUMO
OBJECTIVES: To perform the first validation study of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (finPCPTRC) in a contemporary referral population in Mexico. METHODS: 837 patients referred to the Instituto Nacional de Cancerología, Mexico City, Mexico, between 2005 and 2009 were used to validate the finPCPTRC by examining various measures of discrimination and calibration. Net benefit curve analysis was used to gain insight into the use of the finPCPTRC for clinical decisions. RESULTS: Prostate cancer (PCa) incidence (72.8%) was high in this Mexican referral cohort and 45.7% of men who were diagnosed with PCa had high-grade lesions (HGPCa, Gleason score >6). 1.3% of the patients were taking finasteride. The finPCPTRC was a superior diagnostic tool compared to prostate-specific antigen alone when discriminating patients with PCa from those without PCa (AUC = 0.784 vs. AUC = 0.687, p < 0.001) and when discriminating patients with HGPCa from those without HGPCa (AUC = 0.768 vs. AUC = 0.739, p < 0.001). The finPCPTRC underestimated the risk of PCa but overestimated the risk of HGPCa (both p < 0.001). Compared with other strategies to opt for biopsy, the net benefit would be larger with utilization of the finPCPTRC for patients accepting higher risks of HGPCa. CONCLUSIONS: Rates of biopsy-detectable PCa and HGPCa were high and 1.3% of this referral cohort in Mexico was taking finasteride. The risks of PCa or HGPCa calculated by the finPCPTRC were not well calibrated for this referral Mexican population and new clinical diagnostic tools are needed.
Assuntos
Inibidores de 5-alfa Redutase/uso terapêutico , Antineoplásicos Hormonais/uso terapêutico , Finasterida/uso terapêutico , Programas de Rastreamento/métodos , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/tratamento farmacológico , Encaminhamento e Consulta , Fatores Etários , Idoso , Biópsia , Distribuição de Qui-Quadrado , Exame Retal Digital , Predisposição Genética para Doença , Humanos , Incidência , Modelos Logísticos , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Análise Multivariada , Gradação de Tumores , Razão de Chances , Linhagem , Valor Preditivo dos Testes , Prognóstico , Modelos de Riscos Proporcionais , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/sangue , Neoplasias da Próstata/epidemiologia , Neoplasias da Próstata/genética , Neoplasias da Próstata/patologia , Reprodutibilidade dos Testes , Estudos Retrospectivos , Medição de Risco , Fatores de RiscoRESUMO
Introducción. Desde 1948, la exenteración pélvica ha sido la alternativa de tratamiento en el rescate para pacientes con recurrencia por cáncer en la pelvis, sobre todo de tipo ginecológico. El procedimiento original ha sido modificado infinidad de ocasiones en un intento por mejorar el estado general y la calidad de vida de las pacientes sometidas a esta intervención. Objetivo. Efectuamos una revisión de la literatura y transmitimos la evaluación sobre el abordaje integral de las pacientes con recurrencia por cáncer ginecológico, con especial énfasis en el manejo perioperatorio estándar de las pacientes candidatas a esta intervención. Material y métodos. Revisión de la literatura, y análisis crítico de los departamentos involucrados, en el manejo perioperatorio de estas pacientes. Se describen con detalle desde el proceso de selección de las mujeres candidatas, rutas de manejo, monitoreo, evaluaciones preoperatorias, técnica quirúrgica más comúnmente empleada en el Instituto Nacional de Cancerología, hasta los cuidados posoperatorios y seguimiento de las pacientes. Resultados. Resultados. La selección meticulosa de las pacientes candidatas al procedimiento se inicia desde la primera entrevista con evaluación del entorno de la pacientes, soporte familiar, factibilidad económica y decision final por parte de la paciente. Participación de un equipo quirúrgico y de enfermería, multidisplinario, familiarizado con el procedimiento y colaborando sincrónicamente en las fases exenterativa y de reconstrucción. Apego y compromiso en la vigilancia estrecha del posoperatorio y evolución a corto, mediano y largo plazo de las pacientes. Conclusiones. El éxito de este tipo de procedimiento requiere pacientes bien seleccionadas, en centro oncológicos de experiencia, participación multidisciplinaria durante la resección quirúrgica, pero sobre todo del compromiso real por parte del equipo quirúrgico y de enfermería durante el manejo posoperatorio